[147 Pages Report] The molecular cytogenetics market is projected to reach USD 2.52 Billion by 2021 from USD 1.55 Billion in 2016, at a CAGR of 10.1% from 2016 to 2021. The high incidence and large economic burden of genetic disorders and cancer and rise in healthcare expenditure has resulted in the increasing use of molecular cytogenetic products in clinical and research laboratories, academic research institutes, and pharmaceutical and biotechnology companies. The base year considered for the study is 2015, and the forecast has been provided for the period between 2016 and 2021.

Market Dynamics

Drivers

Increasing Incidence of Genetic Disorders and Cancer

Growing Focus on Targeted Cancer Treatment

Increasing Aging Population and Subsequent Rise in Prevalence of Chronic Diseases

Increasing Penetration of Molecular Cytogenetics in Clinical Pathological Testing

Restraint

High Cost of Advanced Instruments

Unfavourable Reimbursement Scenario

Opportunities

Untapped Emerging Markets in Asia

Trends

Transition From Fish to Array-Based Techniques

The objectives of this study are as follows:

To define, describe, and forecast the global molecular cytogenetics market by product, technique, application, end user, and region

To provide detailed information regarding the major factors influencing market growth (drivers, restraints, and opportunities)

To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall molecular cytogenetics market

To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders

To forecast the size of the market segments with respect to four main regions, namely, North America, Europe, Asia, and the Rest of the World (RoW)

To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies

To track and analyze competitive developments such as product launches, agreements, expansions, acquisitions, and other developments in the global molecular cytogenetics market

Research Methodology

Top-down and bottom-up approaches were used to estimate and validate the size of the global molecular cytogenetics market and to estimate the size of various other dependent submarkets. The overall market size was used in the top-down approach to estimate the sizes of other individual markets (mentioned in the market segmentation�by products and region) through percentage splits from secondary and primary research. The bottom-up approach was also implemented (wherever applicable) for data extracted from secondary research to validate the market segment revenues obtained.

Various secondary sources referred to for this research study include publications from government sources such as the white papers; articles from recognized authors; gold standard and silver standard websites, directories, and databases; corporate filings such as annual reports, SEC filings, investor presentations, and financial statements; research journals; press releases; and trade, business, and professional associations have been used to identify and collect information useful for this extensive commercial study of the molecular cytogenetics market. Primary sources such as experts from related industries and suppliers have been interviewed to obtain and verify critical information as well as to assess prospects of the molecular cytogenetics market. The breakdown of profiles of primaries is shown in the figure below:

To know about the assumptions considered for the study, download the pdf brochure

The major players in the molecular cytogenetics market are F. Hoffmann-La Roche Ltd. (Switzerland) Danaher Corporation (US), Thermo Fisher Scientific, Inc. (US), Abbott Laboratories (US), Agilent Technologies (US), PerkinElmer, Inc. (US), Illumina, Inc. (US), Bio-Rad Laboratories (US), Oxford Gene Technology (UK), and Applied Spectral Imaging (US).

Target Audience for this Report:

Manufacturers and Suppliers of Molecular Cytogenetics Instruments and Consumables

Clinical and Research Laboratories

Pharmaceutical and Biotechnology Companies

Academic Research Institutes related to Molecular Cytogenetics Market

Venture Capitalists and Investors

Value Addition for the Buyer:

This report provides insights into the global molecular cytogenetics market. It provides valuable information on the products, applications, and regions in the molecular cytogenetics market. The geographic analysis for these segments is also presented in this report. Leading players in the market are profiled to study their device offerings and understand strategies undertaken by them to be competitive in this market.

The above-mentioned information would help the buyer understand market dynamics. In addition, the forecasts provided in the report will enable firms to understand the trends in this market and better position themselves to capitalize on the growth opportunities.

Major Market Developments

In January 2014, Roche acquired Genia Technologies, Inc. (U.S.). This acquisition strengthened Roche's Next Generation Sequencing pipeline.

In February 2015, Roche acquired Signature Diagnostics AG (Germany).

In January 2016, Thermo Fisher Scientific, Inc. acquired Affymetrix (U.S.). This acquisition strengthened Thermo Fisher Scientific's leadership into bioscience business and create new market opportunities in genetic analysis.

In July 2016, Thermo Fisher Scientific and HEALTH BioMed (China) collaborated to support HBM�s development of molecular diagnostic kits for infectious diseases and pharmacogenomics screening which will serve the Chinese market.

Critical questions the report answers

How the market developments of key players impact the overall industry?

What are the restraining factors for the molecular cytogenetics market?

Targeted therapies differ from standard chemotherapy in several ways. These therapies act on specific molecular targets associated with cancer, whereas most standard chemotherapies act on all rapidly dividing normal and cancerous cells. In solid tumors, significantly high levels of chromosome abnormalities have been detected, but distinction between critical and irrelevant events has been a major challenge. The emergence of molecular-based cytogenetic techniques such as fluorescence in situ hybridization is particularly useful for solid malignancies, and the spectrum of their application is rapidly expanding to improve efficiency and sensitivity in cancer prevention, diagnosis, prognosis, and therapy selection, alone or in combination with other diagnostic methods. The increasing use for molecular cytogenetics in clinical oncology will drive the growth of the global molecular cytogenetics market.

Scope of the Report:

This report categorizes the molecular cytogenetics market into the following segments:

Molecular Cytogenetics Market, By Product

Kits & Reagents Testing Kits Probes Fluorescent Affinity Reagents Other Kits & Reagents

Instruments

Consumables

Software & Services

Molecular Cytogenetics Market, By Technique

Comparative Genomic Hybridization Array-Based Comparative Genomic Hybridization Standard Comparative Genomic Hybridization

Fluorescence in Situ Hybridization

In Situ Hybridization

Other Techniques

Molecular Cytogenetics Market, By Application

Genetic Disorders

Cancer

Personalized Medicine

Other Applications

Molecular Cytogenetics Market, By End User

Clinical & Research Laboratories

Academic Research Institutes

Pharmaceutical and Biotechnology Companies

Other End Users

Molecular Cytogenetics Market, by Region

North America US Canada

Europe

Asia China Japan India RoA

Rest of the World (RoW)

Customization Options:

Company Information: Detailed company profiles of five or more market players

Opportunities Assessment: A detailed report underlining the various growth opportunities presented in the market.

The molecular cytogenetics market is projected to reach USD 2.52 Billion by 2021 from USD 1.55 Billion in 2016, at a CAGR of 10.1% from 2016 to 2021. The high incidence and large economic burden of genetic disorders and cancer and rise in healthcare expenditure has resulted in the increasing use of molecular cytogenetic products in clinical and research laboratories, academic research institutes, and pharmaceutical and biotechnology companies.

The molecular cytogenetics market is segmented based on products, techniques, application, end user, and region. On the basis of product, the market is segmented into kits and reagents, instruments, consumables, and software and services. The kits and reagents segment is expected to account for the largest share of the global market in 2016; the increasing incidence of genetic disorders and cancer is a key market driver in this segment.

On the basis of technique, the market is segmented into comparative genomic hybridization (CGH), fluorescence in situ hybridization (FISH), in situ hybridization (ISH), and other techniques. CGH forms the largest and fastest-growing technology segment of this market, as the increasing laboratory automation will increase areas of application of CGH in molecular cytogenetics market.

Based on application, the molecular cytogenetics market is segmented into genetic disorders, cancer, personalized medicine, and other applications. The genetic disorders segment accounts for the largest share of the global market in 2016; and on the basis of end users, the market is segmented into clinical and research laboratories, academic research institutes, pharmaceutical and biotechnology companies, and others. The clinical and research laboratories segment is expected to account for the largest share of the global market in 2016.

The global molecular cytogenetics market is segmented into four major regions North America, Europe, Asia, and Rest of the World. Geographically, the global market is dominated by North America. Growth in the North American segment is primarily driven by the high incidence of genetic disorders and cancer, rapid growth in the aging population, and high healthcare expenditure.

High Cost of Advanced Instruments Will Restrain the Growth of this Market

The implementation of molecular cytogenetics in clinical & research laboratories requires high capital investments. The instruments needed for cytogenetics research and procedures are expensive since they are equipped with advanced features and functionalities. Owing to their high costs, companies and research institutes with smaller R&D budgets cannot afford to purchase or produce such expensive instruments.

On the other hand, pharmaceutical companies will require many such systems to maintain efficiency, and hence their capital cost increases significantly. Furthermore, academic research laboratories find it difficult to invest in such systems as they have controlled budgets. In developing countries owing to budget constraints, small- and medium-sized hospitals and clinical pathology laboratories cannot afford high priced, fully automated, technologically advanced instruments.

Another major barrier is the complexity of manufacturing cytogenetics kits & reagents, probes, and instruments. The development process for cytogenetics products is highly complex and costly that requires significant investments, technical capabilities, clinical trial expertise, scientific standards, and quality systems. End users who do not require regular molecular cytogenetics testing and have low budgets are therefore reluctant towards the implementation of advanced systems. This is restraining the growth of this market.

Key players in the molecular cytogenetics market include F. Hoffmann-La Roche Ltd. (Switzerland) Danaher Corporation (US), Thermo Fisher Scientific, Inc. (US), Abbott Laboratories (US), Agilent Technologies (US), PerkinElmer, Inc. (US), Illumina, Inc. (US), Bio-Rad Laboratories (US), Oxford Gene Technology (UK), and Applied Spectral Imaging (US).

To speak to our analyst for a discussion on the above findings, click Speak to Analyst